
capit alloc strategi
feedback meet
follow quarter sat biogen cfo head ir
discuss recent result stori head
overal came away meet cfo jeffrey capello vice-president ir
joseph mara greater convict unlik make larger
commit share repurchas support commerci execut
exist franchis capit alloc manag highlight ex-
us price reimburs environ challeng factor made
 less appeal compani recent past continu believ
disciplin approach right one howev see intensifi
competit ms sma underscor urgent need transact
help improv revenu growth prospect nearer-term given commentari
start envis scenario continu large-scal share
repurchas remain current author someth
earlier-stag pipelin bear fruit look known asset biogen
pipelin see mani asset like drive growth near-term off-set
eros oral gener novel competit ms competit
zolgensma like risdiplam sma buyback like support
stock near-term help ep growth believ headwind across
market portfolio increasingli like drive multipl compress
absent unexpect pipelin success meaning bd reiter
under-perform rate tp
valuat metric
number share
price month
 close
suiss seek busi compani cover research report result investor awar
firm may conflict interest could affect object report investor consid report
singl factor make invest decis
inc biopharmaceut compani engag
discov develop deliv therapi neurolog
neurodegen diseas
profit tax
associ
chang work capit
flow oper
free cash-flow firm
flow invest
chang net cash/debt
total liabil equiti
share wtd average
price book
roe stated-return
experi greater expect degre eros
competit eros occur partial off-set sale
vumer spinraza remain standard care sma
risdiplam zolgensma either fail clinic take
meaning share share repurchas lead meaning
accret constant improv multipl
grey scenario assum ms franchis declin
greater expect rate new therapi take greater
expect share near-term zolgensma captur major
new incid sma market long-term spinraza lose share
risdiplam preval sma market capit
deploy strategi fail gener meaning earn growth
share experi even greater degre multipl
 close
pipelin asset could address larg unmet market although clinic data
earli assign meaning valu manag highlight sever
import pipelin asset compani believ could diversifi revenu long-term
key asset includ phase data expect progress supranuclear
palsi psp data parkinson diseas pd data
system lupu erythematosu sle agre target could address
larg market high unmet need us preval pd patient psp sle
howev still need see advanc clinic data comfort
asset given challeng develop neurosci drug consid
diseas popul would expect larger later-stag random control clinic
trial necessari gain fda approv unlik oncolog drug
approv smaller earlier-stag trial end await de-risk clinic data
ahead assign meaning valu valuat model
highlight compani intent focu de-risk improv
overal health busi plan implement strategi
priorit asset valid target biomark termin pipelin
asset failur low po earlier develop process agre
could streamlin spend relev asset remain seen
strategi play practic would prefer see greater focu high impact
asset accret bd achiev meaning growth
overal greatli appreci opportun sit
manag especi given neg view stock
convers chang thesi concern manag
seem will implement larger structur chang strategi think
need acquir becom increasingli import especi potenti
slow growth declin ms coupl like headwind sma also
concern upcom ipr challeng patent protect tecfidera
lost could significantli alter cash-flow gener ms franchis
see note potenti outcom
compar large-cap peer long-term set becom
increasingli challeng gilead face similar growth issu begun address
evidenc recent transact galapago much larger
biosimilar busi could help restor revenu growth despit neg growth
current base busi also see upsid emerg oncolog portfolio
name tezepelumab vertex continu best revenu
earn growth profil coupl ampl capac yet urgent need engag
 declin base busi headwind expect current
growth area spinraza increas need transact posit compani buyer
weak think set combin weaker higher-risk pipelin like
caus share under-perform next year
compani mention price
